Translational Technologies International Awarded CDC’S TAMS IDIQ

Translational Technologies International (TTI), a public health research and consulting company, announced that it was recently awarded the Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion’s (NCCDPHP) Technical and Management Support for Health Promotion (TAMS) Indefinite Delivery, Indefinite Quantity Contract (IDIQ) contract.

As part of the 5-year, approximately 61 million dollar contract, TTI will provide CDC/NCCDPHP with a variety of support services, including technical assistance, health education activities, assessments, demonstration projects, studies, and research activities.

“We’re excited and privileged to have the opportunity to work with CDC and NCCDPHP.” said TTI’s President and CEO, Dr. April Zambelli-Weiner. “TTI has assembled a team of seasoned, high-quality professionals across multiple disciplines to excel at a wide range of task orders. We look forward to working with our partners and leveraging our expertise in the prevention and management of chronic disease to bring top-tier solutions to CDC and NCCDPHP.”

This IDIQ is designed to provide CDC with focused, high-priority evaluation, research and technical assistance activities in support of NCCDPHP. As part of this contract, TTI will undertake research and evaluation studies to help improve the health and well-being of individuals, families, and communities.

More about this opportunity and NCCDPHP:

About the EDWOSB designation and small business opportunities, through the U.S. Small Business Administration’s (SBA) website:



TTi Research